Cardiovascular morbidity and mortality associated with the metabolic syndrome

OBJECTIVE - To estimate the prevalence of and the cardiovascular risk assoc iated with the metabolic syndrome using the new definition proposed by the World Health Organisation (WHO). RESEARCH DESIGN AND METHODS - A total of 4,483 subjects aged 35-70 years pa rticipating in a large family study of type 2 diabetes in Finland and Swede n (the Botnia study) were included in the analysis of cardiovascular risk a ssociated with the metabolic syndrome. in subjects who had type 2 diabetes in = 1,697) impaired fasting glucose (IFG)/impaired glucose tolerance (IGT) (n = 798), or insulin-resistance with normal glucose tolerance (NGT) (n = 1,988). the metabolic syndrome was de fined as presence of at least two of the following risk factors: obesity hypertension, dyslipidemia, or microalb uminuria. Cardiovascular mortality was assessed in 3,606 subjects with a me dian follow-up of 6.9 years. RESULTS - In women and men, respectively, the metabolic syndrome was seen i n 10 and 15% of subjects with NGT. 42 and 64% of those with IFG/IGT, and 78 and 84% of those with type 2 diabetes. The risk for coronary heart disease and stroke was increased threefold in subjects with the syndrome (P < 0.00 1). Cardiovascular mortality was markedly increased in subjects with the me tabolic syndrome (12.0 vs. 2.2%, P < 0.001) Of the individual components of the metabolic syndrome, microalbuminuria conferred the strongest risk of c ardiovascular death (RR 2.80. P = 0.002). CONCLUSIONS - The WHO definition of the metabolic syndrome identifies subje cts with increased cardiovascular morbidity and mortality and offers a tool for comparison of results from different studies.